Clinical trial NCT04158310: Evaluation the Clinical Value of Xiyanping Injection in the Treatment of Community-acquired Pneumonia in Children
Official title: Evaluation of Clinical Value and Safety of Xiyanping Injection in the Treatment of Community-acquired Pneumonia in Children Based on Real-world Clinical Data
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Community Acquired Pneumonia
Lead sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Sponsor class: INDUSTRY
First posted: 2019-11-08
Enrollment: 9207
Sex: ALL
Minimum age (years): 2
Maximum age (years): 14
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 2 years old \< age ≤ 14 years old children, male or female, diagnosed as community-acquired pneumonia diagnosed and need hospitalization

Brief summary: In order to verify the clinical value and safety of Xiyanping injection in children with CAP, we intend to carry out this multi-center, large-sample, non-intervention clinical research through more rigorous and scientific design. Considering the current status of clinical research in children in China,research use real-world research methods.

Detailed description: This is an real world study of efficacy and safety of intravenous injection of Xiyanping injection in pediatric subjects with CAP.The purpose to determine the clinical value and influencing factors of Xiyanping injection in the treatment of community-acquired pneumonia in children based on real-world clinical data. The starting point for the study was the time at which the patient started treatment with Xiyanping injection or using a conventional treatment regimen; the end of follow-up was the date of the last visit to the patient, and if the patient had a disease progression or transfer, the date of the occurrence was the end. At the same time, baseline demographic characteristics (gender, date of birth, type of medical insurance, etc.), therapeutic drugs during the follow-up period, dose and time of use, laboratory indicators (such as white blood cells, C-reactive protein, etc., and examination time) were collected.

Eligibility criteria: Inclusion criteria:

* 2 years old \< age ≤ 14 years old children, male or female, diagnosed as community-acquired pneumonia diagnosed and need hospitalization

Exclusion criteria:

* Acute infectious diseases such as measles, whooping cough, and influenza
* Other concomitant diseases or conditions that the investigators believe may interfere with the study, such as severe primary disease with severe heart, liver, kidney, digestive, and hematopoietic systems
* Children with severe malnutrition and previous history of immunodeficiency may seriously affect the self-limiting course of the disease
* Children with epilepsy and other central nervous system dysfunction
* Congenital diseases, mental patients
* Those who have used systemic hormones within 2 weeks before enrollment;
* Those who have used Qingrejiedu Chinese medicine within 2 weeks before enrollment
* The subject is poorly compliant (not according to the doctor's prescription or medical advice) or fails to timely feedback information

Primary outcomes:
measure: Time to Alleviation of Cough and Lung X-ray
timeFrame: 7 days
measure: Time to Alleviation of Body Temperature
timeFrame: 7 days
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: